As the Covid-19 booster vaccination campaign gets underway in France, a new publication of the results of the Cannemuss observational study (supported by the AFM-Téléthon and carried out by Bordeaux University Hospital) shows that :
- 90.1% of the 33 participants suffering from various neuromuscular diseases that had induced severe muscular atrophy had a serum level of anti-S antibodies considered to be protective, with strong neutralising activity, six weeks after two doses of a messenger RNA anti-Covid-19 vaccine,
- 36.3% of participants retained high levels of anti-S at week 24,
- of the remaining patients, 22 received a single booster vaccination, which restored high levels of anti-S and significant neutralising activity, benefits that were still present 29 weeks after the injection.
None of the participants developed symptomatic Covid-19 during the year of the study. Three of them reported an asymptomatic form.
